3D QSAR and pharmacophore identification of isoquinoline and benzimidazole analogs as potent C-RAF inhibitors..

Author(s): Blessy Christina N.*, Manoj Kumar Mahto, Uday Kumar Dasari, Matcha Bhaskar

Abstract

The C-Raf inhibitors obstruct the activity of other signaling pathways which are implicated in many tumors. Hence C-RAF inhibition has emerged as a promising therapeutic target for many cancers. A series of 33 novel Isoquinoline and benzimidazole derivatives has been reported as C-RAF inhibitors. A combined study of pharmacophore prediction, atom based 3d QSAR and molecular docking explored the structural insights of these inhibitors. A Five point pharmacophore hypothesis AADHR. 719 yielded a statistically significant 3D QSAR model with PLS factors as r2= 0.93, Q2= 0.51, RMSE=0.177. Docking study also revealed the binding orientations of active ligand 10e at active site amino acid residue (GLU478, GLN610, PHE443) of C-Raf. The results of ligand based pharmacophore hypothesis and atom based 3D QSAR highlighted the important binding features of novel Isoquinoline and Benzimidazole derivaties as potent C-Raf inhibitors.

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.